Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07522242
PHASE2

Safety and Efficacy of T10430 Eye Drops in Controlling Paediatric Myopia Progression

Sponsor: Laboratoires Thea

View on ClinicalTrials.gov

Summary

Axial myopia is a type of nearsightedness that happens when the eye is too long from front to back. This causes distant vision to be blurry. Axial myopia tends to start during childhood and worsens over time (as the eyes continue to grow longer). This can lead to serious eye-related conditions later in life. The aim of T10430 treatment is to stop or slow this progression during childhood and therefore, prevent more serious complications. Animal studies using drugs with a similar mechanism of action as T10430 have demonstrated positive safety results. This study aims to better understand the safety and potential effectiveness of T10430 in children with axial myopia.

Key Details

Gender

All

Age Range

6 Years - 11 Years

Study Type

INTERVENTIONAL

Enrollment

200

Start Date

2026-01-21

Completion Date

2027-11

Last Updated

2026-04-13

Healthy Volunteers

No

Conditions

Interventions

DRUG

T10430 lower dose

The participant will be instilled 1 drop of the T10430 in the conjunctival cul-de-sac of each eye, once daily, at 20h00 (±2 hours) from Day 1 to the day before the End of treatment visit (Visit #4).

DRUG

T10430 middle dose

The participant will be instilled 1 drop of the T10430 in the conjunctival cul-de-sac of each eye, once daily, at 20h00 (±2 hours) from Day 1 to the day before the End of treatment visit (Visit #4).

DRUG

T10430 higher dose

The participant will be instilled 1 drop of the T10430 in the conjunctival cul-de-sac of each eye, once daily, at 20h00 (±2 hours) from Day 1 to the day before the End of treatment visit (Visit #4).

DRUG

Vehicle

The participant will be instilled 1 drop of the vehicle in the conjunctival cul-de-sac of each eye, once daily, at 20h00 (±2 hours) from Day 1 to the day before the End of treatment visit (Visit #4).

Locations (10)

Abdali Hospital

Amman, Jordan

Istiklal Hospital

Amman, Jordan

Jordan University Hospital

Amman, Jordan

Irbid Specialty Hospital

Irbid, Jordan

Pharmaceutical research center at Jordan University of Science and Technology

Irbid, Jordan

IATROS INTERNATIONAL PTY Ltd

Brandwag, South Africa

Pretoria Eye Institute Research Foundation

Pretoria, South Africa

Hôpital Universitaire Tahar Sfar Mahdia

Mahdia, Tunisia

Hôpital Farhat-Hached

Sousse, Tunisia

Hôpital Charles Nicolle

Tunis, Tunisia